Michael Gelband’s C4 Therapeutics CCCC Stock Holding History

Michael Gelband’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71M	Buy	580,195 +532,688	+1,121%	+$1.82M	0.02%	705
2026 Q1	$125K	Sell	47,507 -14,658	-24%	-$34.5K	﹤0.01%	1425
2025 Q4	$119K	Buy	+62,165	New	+$147K	﹤0.01%	1427
2025 Q1	–	Sell	-59,654	Closed	-$215K	–	1511
2024 Q4	$215K	Buy	+59,654	New	+$297K	﹤0.01%	1351
2023 Q2	–	Sell	-10,551	Closed	-$33K	–	1881
2023 Q1	$33K	Buy	+10,551	New	+$62.1K	﹤0.01%	1677
2022 Q3	–	Sell	-35,197	Closed	-$265K	–	1916
2022 Q2	$265K	Buy	+35,197	New	+$310K	﹤0.01%	1576

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's CCCC Position: Q2 2026 in Review

Michael Gelband increased its C4 Therapeutics (CCCC) stake by 1,121% in Q2 2026, buying an estimated $1.82M and bringing the position to 580,195 shares worth $2.71M. The position accounts for 0.02% of the portfolio, ranked #705.

Michael Gelband first reported a position in CCCC in Q2 2022 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Michael Gelband held 580,195 shares of C4 Therapeutics worth $2.71M as of Q2 2026.
Michael Gelband bought 532,688 C4 Therapeutics shares in Q2 2026, an estimated $1.82M.
C4 Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #705 holding.
Michael Gelband first reported a position in C4 Therapeutics in Q2 2022 and has held it in 6 quarters since.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.